344(top 1%)
PR articles
13.5K(top 1%)
PR citations
61(top 1%)
PR h-index
66(top 1%)
h-index
407
documents
17.7K
doc citations
2.3K
citing journals
100
times ranked

Publications

346 peer-reviewed articles • 14,023 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1A graph neural network-based model with out-of-distribution robustness for enhancing antiretroviral therapy outcome prediction for HIV-1
Computerized Medical Imaging and Graphics, 2025, 120, 102484
4.617Citations (PDF)
2Inclusive Crisis Communication in a Pandemic Context: A Rapid Review
International Journal of Environmental Research and Public Health, 2024, 21, 1216
2.99Citations (PDF)
3EGHRIN conclusions on pandemic preparedness: no whole-of-society approach without society
BMC Health Services Research, 2024, 24,
2.52Citations (PDF)
4Analysis of mutational history of multidrug‐resistant genotypes with a mutagenetic tree model
Journal of Medical Virology, 2023, 95,
3.64Citations (PDF)
5Virus taxonomy and the role of the International Committee on Taxonomy of Viruses (ICTV)
Journal of General Virology, 2023, 104,
3.375Citations (PDF)
6Analyses of Early ZIKV Genomes Are Consistent with Viral Spread from Northeast Brazil to the Americas
Viruses, 2023, 15, 1236
3.21Citations (PDF)
7High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam
Scientific Reports, 2023, 13,
3.417Citations (PDF)
8Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length Genomes
Viruses, 2023, 15, 2391
3.20Citations (PDF)
9Genome-wide diversity of Zika virus: Exploring spatio-temporal dynamics to guide a new nomenclature proposal
Virus Evolution, 2022, 8,
3.411Citations (PDF)
10Qualitative systems mapping for complex public health problems: A practical guide
PLoS ONE, 2022, 17, e0264463
2.342Citations (PDF)
11The Impact of Genital Ulcers on HIV Transmission Has Been Underestimated—A Critical Review
Viruses, 2022, 14, 538
3.27Citations (PDF)
12Exploring the mechanisms behind HIV drug resistance in sub-Saharan Africa: conceptual mapping of a complex adaptive system based on multi-disciplinary expert insights
BMC Public Health, 2022, 22,
3.120Citations (PDF)
13Learning for the Future: A Case Study of Transdisciplinary Collaboration to Improve Pandemic Preparedness
Transdisciplinary Insights, 2022, 5, 41-54
0.31Citations (PDF)
14Behavioral changes before lockdown and decreased retail and recreation mobility during lockdown contributed most to controlling COVID-19 in Western countries
BMC Public Health, 2021, 21,
3.123Citations (PDF)
15A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic
Viruses, 2021, 13, 1098
3.215Citations (PDF)
16Comparison of two simulators for individual based models in HIV epidemiology in a population with HSV 2 in Yaoundé (Cameroon)
Scientific Reports, 2021, 11,
3.45Citations (PDF)
17Determinants of HIV-1 Late Presentation in Patients Followed in Europe
Pathogens, 2021, 10, 835
2.943Citations (PDF)
18Newly Discovered Archival Data Show Coincidence of a Peak of Sexually Transmitted Diseases with the Early Epicenter of Pandemic HIV-1
Viruses, 2021, 13, 1701
3.21Citations (PDF)
19Factors Associated with HIV Drug Resistance in Dar es Salaam, Tanzania: Analysis of a Complex Adaptive System
Pathogens, 2021, 10, 1535
2.916Citations (PDF)
20Development of HIV Drug Resistance in a Cohort of Adults on First-Line Antiretroviral Therapy in Tanzania during the Stavudine Era
Microbiology Research, 2021, 12, 847-861
2.212Citations (PDF)
21Increasing Prevalence of HIV-1 Transmitted Drug Resistance in Portugal: Implications for First Line Treatment Recommendations
Viruses, 2020, 12, 1238
3.211Citations (PDF)
22Scenario-driven forecasting: modeling peaks and paths. Insights from the COVID-19 pandemic in Belgium
Scientometrics, 2020, 124, 2703-2715
2.45Citations (PDF)
23Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey
Lancet HIV,the, 2020, 7, e772-e781
7.993Citations (PDF)
24Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable
Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12522-12523
7.574Citations (PDF)
25Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework
Viruses, 2020, 12, 645
3.214Citations (PDF)
26Molecular Epidemiology of HIV-1 Infected Migrants Followed Up in Portugal: Trends between 2001–2017
Viruses, 2020, 12, 268
3.217Citations (PDF)
27A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
BMC Medicine, 2020, 18,
7.152Citations (PDF)
28A Transdisciplinary Approach to Get a Deeper Insight in the Context of Ebola Virus Outbreaks in War-torn Regions: A Comprehensive Guide for NGOs
Transdisciplinary Insights, 2020, 4, 48-89
0.32Citations (PDF)
29The Impact of Community Health Workers on HIV Therapy Outcome in Sub-Saharan Africa
Transdisciplinary Insights, 2020, 4, 1-24
0.30Citations (PDF)
30Youngsters' Sustainable Food Choices in the Supermarket
Transdisciplinary Insights, 2020, 4, 130-140
0.30Citations (PDF)
31Genome Detective: an automated system for virus identification from high-throughput sequencing data
Bioinformatics, 2019, 35, 871-873
4.7400Citations (PDF)
32Advances in Visualization Tools for Phylogenomic and Phylodynamic Studies of Viral Diseases
Frontiers in Public Health, 2019, 7,
2.723Citations (PDF)
33Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes
Journal of Hepatology, 2019, 71, 1270-1272
4.27Citations (PDF)
34A computational method for the identification of Dengue, Zika and Chikungunya virus species and genotypes
PLoS Neglected Tropical Diseases, 2019, 13, e0007231
3.084Citations (PDF)
35Tracing the Impact of Public Health Interventions on HIV-1 Transmission in Portugal Using Molecular Epidemiology
Journal of Infectious Diseases, 2019, 220, 233-243
3.731Citations (PDF)
36The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy
Aids, 2019, 33, 315-326
2.56Citations (PDF)
37Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
PLoS ONE, 2019, 14, e0225381
2.315Citations (PDF)
38Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis
Lancet Infectious Diseases, The, 2019, 19, 143-155
16.5385Citations (PDF)
39Prosumers Everywhere: Investigating the Driving Forces Behind Prosumer Behavior in Different Socioeconomic Strata
Transdisciplinary Insights, 2019, 3, 198-218
0.34Citations (PDF)
40HIV-related Peer Support in Dar es Salaam: A Pilot Questionnaire Inquiry
Transdisciplinary Insights, 2019, 3, 1-18
0.34Citations (PDF)
41A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients
OncoImmunology, 2018, 7, e1426423
5.420Citations (PDF)
42HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012
Scientific Reports, 2018, 8,
3.426Citations (PDF)
43Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland
Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 514-522
1.88Citations (PDF)
44The impact of HIV-1 within-host evolution on transmission dynamics
Current Opinion in Virology, 2018, 28, 92-101
5.059Citations (PDF)
45A8 Improving the accuracy and precision of estimated temporal trends in HIV incidence among MSM populations by calibrating agent-based simulation models to phylogenetic tree data
Virus Evolution, 2018, 4,
3.40Citations (PDF)
46HIV-positive men as a key population for fighting HIVDR in Africa
Transdisciplinary Insights, 2018, 2, 78-91
0.31Citations (PDF)
47Time to Harmonize Dengue Nomenclature and Classification
Viruses, 2018, 10, 569
3.216Citations (PDF)
48Ethical considerations in global HIV phylogenetic research
Lancet HIV,the, 2018, 5, e656-e666
7.953Citations (PDF)
49Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
PLoS ONE, 2018, 13, e0201268
2.317Citations (PDF)
50Expert consensus statement on the science of HIV in the context of criminal law
Journal of the International AIDS Society, 2018, 21,
3.478Citations (PDF)
51IFN-β induces greater antiproliferative and proapoptotic effects and increased p53 signaling compared with IFN-α in PBMCs of Adult T-cell Leukemia/Lymphoma patients
Blood Cancer Journal, 2017, 7, e519-e519
5.519Citations (PDF)
52Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning
Infection, Genetics and Evolution, 2017, 53, 15-23
2.316Citations (PDF)
53Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec
Aids, 2017, 31, 707-717
2.534Citations (PDF)
54Phylogenetic evidence for underreporting of male‐to‐male sex among human immunodeficiency virus–infected donors in the Netherlands and Flanders
Transfusion, 2017, 57, 1235-1247
0.814Citations (PDF)
55Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
BMC Evolutionary Biology, 2017, 17,
3.124Citations (PDF)
56PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context
Bioinformatics, 2017, 33, 3993-3995
4.720Citations (PDF)
57A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation
Frontiers in Immunology, 2017, 8,
4.920Citations (PDF)
58A36 Prevalence of HIV-1 subtypes in Slovenia with an emphasis on molecular and phylogenetic investigation of subtype A
Virus Evolution, 2017, 3,
3.40Citations (PDF)
59A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium
Virus Evolution, 2017, 3,
3.47Citations (PDF)
60A18 Random amplification with next-generation sequencing to cover HIV and HCV full-length genomes
Virus Evolution, 2017, 3,
3.41Citations (PDF)
61Transdisciplinary experience in a pilot year of a new Honors Program at the KU Leuven – University of Leuven: building a team, developing and improving a transdisciplinary project through addressing a challenge on HIV drug resistance in Africa
Transdisciplinary Insights, 2017, 1, 33-39
0.30Citations (PDF)
62Quantifying Next Generation Sequencing Sample Pre-Processing Bias in HIV-1 Complete Genome Sequencing
Viruses, 2016, 8, 12
3.216Citations (PDF)
63Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic Review
Frontiers in Microbiology, 2016, 7,
3.926Citations (PDF)
64Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients
International Journal of Molecular Sciences, 2016, 17, 1416
4.419Citations (PDF)
65Male Circumcision and the Epidemic Emergence of HIV-2 in West Africa
PLoS ONE, 2016, 11, e0166805
2.311Citations (PDF)
66HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial
Infection, Genetics and Evolution, 2016, 44, 169-181
2.33Citations (PDF)
67On the contribution of Angola to the initial spread of HIV-1
Infection, Genetics and Evolution, 2016, 46, 219-222
2.314Citations (PDF)
68Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time
Reviews in Medical Virology, 2016, 26, 408-434
6.741Citations (PDF)
69Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development
Virus Evolution, 2016, 2, vew024
3.417Citations (PDF)
70The global spread of HIV-1 subtype B epidemic
Infection, Genetics and Evolution, 2016, 46, 169-179
2.366Citations (PDF)
71Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations
AIDS Research and Human Retroviruses, 2016, 32, 427-433
1.421Citations (PDF)
72Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution
Aids, 2015, 29, 1549-1556
2.517Citations (PDF)
73Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals
Aids, 2015, 29, 2045-2052
2.523Citations (PDF)
74Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance
Viruses, 2015, 7, 5018-5039
3.265Citations (PDF)
75Performance of an In-House Human Immunodeficiency Virus Type 1 Genotyping System for Assessment of Drug Resistance in Cuba
PLoS ONE, 2015, 10, e0117176
2.36Citations (PDF)
76Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis
PLoS Medicine, 2015, 12, e1001810
8.0200Citations (PDF)
77HIV-1 genotypic drug resistance testing: digging deep, reaching wide?
Current Opinion in Virology, 2015, 14, 16-23
5.039Citations (PDF)
78Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe
BMC Infectious Diseases, 2015, 15,
2.611Citations (PDF)
79An integrated map of HIV genome-wide variation from a population perspective
Retrovirology, 2015, 12,
3.5120Citations (PDF)
80A new ensemble coevolution system for detecting HIV-1 protein coevolution
Biology Direct, 2015, 10,
4.388Citations (PDF)
81CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba
EBioMedicine, 2015, 2, 244-254
9.763Citations (PDF)
82Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine
Clinical Microbiology and Infection, 2015, 21, 607.e1-607.e8
5.314Citations (PDF)
83Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia
Journal of Infectious Diseases, 2015, 211, 1735-1744
3.772Citations (PDF)
84Discovery and Characterization of Auxiliary Proteins Encoded by Type 3 Simian T-Cell Lymphotropic Viruses
Journal of Virology, 2015, 89, 931-951
3.62Citations (PDF)
85Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic
PLoS ONE, 2014, 9, e101738
2.338Citations (PDF)
86Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings
BMC Public Health, 2014, 14,
3.199Citations (PDF)
87HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes
Retrovirology, 2014, 11,
3.513Citations (PDF)
88The Genealogical Population Dynamics of HIV-1 in a Large Transmission Chain: Bridging within and among Host Evolutionary Rates
PLoS Computational Biology, 2014, 10, e1003505
3.184Citations (PDF)
89CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Journal of Neuroinflammation, 2014, 11,
9.031Citations (PDF)
90A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity
Antiviral Research, 2014, 112, 91-102
3.827Citations (PDF)
91A near-full length genotypic assay for HCV1b
Journal of Virological Methods, 2014, 209, 126-135
1.611Citations (PDF)
92Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits
Virology, 2014, 456-457, 310-318
2.36Citations (PDF)
93Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase
Acta Clinica Belgica, 2014, 69, 348-357
1.43Citations (PDF)
94Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group
PLoS ONE, 2014, 9, e94495
2.337Citations (PDF)
95HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes
Retrovirology, 2014, 11, 79
3.51Citations (PDF)
96Limited cross-border infections in patients newly diagnosed with HIV in Europe
Retrovirology, 2013, 10,
3.553Citations (PDF)
97HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
Retrovirology, 2013, 10,
3.5139Citations (PDF)
98Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania
BMC Public Health, 2013, 13,
3.168Citations (PDF)
99HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure
Infection, Genetics and Evolution, 2013, 19, 349-360
2.34Citations (PDF)
100Viral phylogeny in court: the unusual case of the Valencian anesthetist
BMC Biology, 2013, 11,
3.915Citations (PDF)
101Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba
Infection, Genetics and Evolution, 2013, 16, 144-150
2.323Citations (PDF)
102Mutations selected in HIV-2-infected patients failing a regimen including atazanavir
Journal of Antimicrobial Chemotherapy, 2013, 68, 190-192
3.118Citations (PDF)
103Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools
Infection, Genetics and Evolution, 2013, 19, 337-348
2.3385Citations (PDF)
104Asparagine 42 of the conserved endo‐inulinase INU2 motif WMNDPN from Aspergillus ficuum plays a role in activity specificity
FEBS Open Bio, 2013, 3, 467-472
2.214Citations (PDF)
105Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences
Journal of Virological Methods, 2013, 193, 135-139
1.61Citations (PDF)
106HIV-1 Drug Resistance: Where do Polymorphisms Fit in?
Future Microbiology, 2013, 8, 303-306
2.011Citations (PDF)
107RegaDB: community-driven data management and analysis for infectious diseases
Bioinformatics, 2013, 29, 1477-1480
4.729Citations (PDF)
108Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir
Journal of Antimicrobial Chemotherapy, 2013, 68, 419-423
3.14Citations (PDF)
109The demise of multidrug-resistant HIV-1: the national time trend in Portugal
Journal of Antimicrobial Chemotherapy, 2013, 68, 911-914
3.17Citations (PDF)
110Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe
Journal of Infectious Diseases, 2013, 207, 1216-1220
3.757Citations (PDF)
111Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen
Journal of Antimicrobial Chemotherapy, 2013, 68, 2205-2209
3.18Citations (PDF)
112Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort
BMC Infectious Diseases, 2013, 13,
2.610Citations (PDF)
113Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response
PLoS ONE, 2013, 8, e61436
2.317Citations (PDF)
114Managing Resistance to Anti-HIV Drugs
Drugs, 2012, 57, 337-361
11.426Citations (PDF)
115Ascorbic Acid Has Superior Ex Vivo Antiproliferative, Cell Death-Inducing and Immunomodulatory Effects over IFN-α in HTLV-1-Associated Myelopathy
PLoS Neglected Tropical Diseases, 2012, 6, e1729
3.022Citations (PDF)
116Enhanced Heterosexual Transmission Hypothesis for the Origin of Pandemic HIV-1
Viruses, 2012, 4, 1950-1983
3.212Citations (PDF)
117HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G
Journal of Antimicrobial Chemotherapy, 2012, 67, 1075-1079
3.18Citations (PDF)
118Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
Retrovirology, 2012, 9,
3.523Citations (PDF)
119Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines
Virology Journal, 2012, 9,
3.623Citations (PDF)
120Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A
Journal of General Virology, 2012, 93, 889-899
3.362Citations (PDF)
121High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba
Journal of Clinical Virology, 2012, 55, 348-355
3.011Citations (PDF)
122Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon
Infection, Genetics and Evolution, 2012, 12, 453-460
2.352Citations (PDF)
123A Public HTLV-1 Molecular Epidemiology Database for Sequence Management and Data Mining
PLoS ONE, 2012, 7, e42123
2.316Citations (PDF)
124European guidelines on the clinical management of HIV-1 tropism testing
Lancet Infectious Diseases, The, 2011, 11, 394-407
16.5227Citations (PDF)
125Appearance of a Single Amino Acid Insertion at Position 33 in HIV Type 1 Protease Under a Lopinavir-Containing Regimen, Associated with Reduced Protease Inhibitor Susceptibility
AIDS Research and Human Retroviruses, 2011, 27, 1223-1229
1.40Citations (PDF)
126Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study)
HIV Medicine, 2011, 12, 211-218
2.837Citations (PDF)
127Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
Journal of Antimicrobial Chemotherapy, 2011, 66, 1886-1896
3.156Citations (PDF)
128Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape
BMC Bioinformatics, 2010, 11,
3.014Citations (PDF)
129The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide
Antiviral Research, 2010, 86, 253-260
3.810Citations (PDF)
130Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G
Infection, Genetics and Evolution, 2010, 10, 373-379
2.39Citations (PDF)
131Comparative performance of the REGA subtyping tool version 2 versus version 1
Infection, Genetics and Evolution, 2010, 10, 380-385
2.316Citations (PDF)
132Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time
PLoS ONE, 2010, 5, e11505
2.359Citations (PDF)
133DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
PLoS ONE, 2010, 5, e13687
2.3163Citations (PDF)
134Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
PLoS ONE, 2010, 5, e13753
2.321Citations (PDF)
135High GUD Incidence in the Early 20th Century Created a Particularly Permissive Time Window for the Origin and Initial Spread of Epidemic HIV Strains
PLoS ONE, 2010, 5, e9936
2.358Citations (PDF)
136Cellular HIV-1 DNA Levels in Drug Sensitive Strains Are Equivalent to Those in Drug Resistant Strains in Newly-Diagnosed Patients in Europe
PLoS ONE, 2010, 5, e10976
2.310Citations (PDF)
137Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
PLoS ONE, 2009, 4, e4724
2.3880Citations (PDF)
138Quantifying Differences in the Tempo of Human Immunodeficiency Virus Type 1 Subtype Evolution
Journal of Virology, 2009, 83, 12917-12924
3.691Citations (PDF)
139Predictive Value of HIV‐1 Genotypic Resistance Test Interpretation Algorithms
Journal of Infectious Diseases, 2009, 200, 453-463
3.740Citations (PDF)
140Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs
Journal of Clinical Microbiology, 2009, 47, 2232-2242
4.013Citations (PDF)
141Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G
Journal of Antimicrobial Chemotherapy, 2009, 63, 593-599
3.118Citations (PDF)
142Development and Validation of a Multiplex Real-Time PCR Assay for Simultaneous Genotyping and Human T-Lymphotropic Virus Type 1, 2, and 3 Proviral Load Determination
Journal of Clinical Microbiology, 2009, 47, 3682-3691
4.039Citations (PDF)
143Transmission of Drug‐Resistant HIV‐1 Is Stabilizing in Europe
Journal of Infectious Diseases, 2009, 200, 1503-1508
3.7217Citations (PDF)
144Relating increasing hantavirus incidences to the changing climate: the mast connection
International Journal of Health Geographics, 2009, 8, 1
2.5216Citations (PDF)
145The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir☆
Infection, Genetics and Evolution, 2009, 9, 683-688
2.38Citations (PDF)
146Comparison of three ELISAs for the routine diagnosis of human T-lymphotropic virus infection in a high-prevalence setting in Peru
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, 103, 420-422
1.314Citations (PDF)
147Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes
Journal of Clinical Virology, 2009, 44, 325-328
3.013Citations (PDF)
148Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
Retrovirology, 2009, 6,
3.5118Citations (PDF)
149A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences
Nucleic Acids Research, 2009, 37, W634-W642
15.5147Citations (PDF)
150Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment
Antiviral Therapy, 2009, 14, 433-442
1.939Citations (PDF)
151Change in hepatitis C virus genotype in hemodialysis patients after end‐of‐treatment response to interferon monotherapy—relapse or re‐infection?
Journal of Medical Virology, 2008, 80, 80-86
3.69Citations (PDF)
152The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium
Journal of Viral Hepatitis, 2008, 15, 399-408
1.918Citations (PDF)
153A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes
Journal of Virological Methods, 2008, 153, 176-181
1.658Citations (PDF)
154The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in Portugal
Retrovirology, 2008, 5, 12
3.543Citations (PDF)
155HIV-1 gp120 N-linked glycosylation differs between plasma and leukocyte compartments
Virology Journal, 2008, 5,
3.617Citations (PDF)
156Prevalence and Epidemiology of HIV Type 1 Drug Resistance among Newly Diagnosed Therapy-Naive Patients in Belgium from 2003 to 2006
AIDS Research and Human Retroviruses, 2008, 24, 355-362
1.434Citations (PDF)
157Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates
Journal of Antimicrobial Chemotherapy, 2008, 61, 1201-1204
3.118Citations (PDF)
158Bayesian network analyses of resistance pathways against efavirenz and nevirapine
Aids, 2008, 22, 2107-2115
2.521Citations (PDF)
159Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment
Bioinformatics, 2008, 24, 34-41
4.727Citations (PDF)
160Early Sequential Development of Infective Dermatitis, Human T Cell Lymphotropic Virus Type 1-Associated Myelopathy, and Adult T Cell Leukemia/Lymphoma
Clinical Infectious Diseases, 2008, 46, 440-442
5.245Citations (PDF)
161Diagnostic Value of Different Adherence Measures Using Electronic Monitoring and Virologic Failure as Reference Standards
AIDS Patient Care and STDs, 2008, 22, 735-743
2.684Citations (PDF)
162Impact on Replicative Fitness of the G48E Substitution in the Protease of HIV-1
Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 255-262
1.86Citations (PDF)
163Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response
Antiviral Therapy, 2008, 13, 399-408
1.917Citations (PDF)
164Adult T-Cell Leukemia/Lymphoma With a Mixed CD4+ and CD8+ Phenotype and Indolent Course
Journal of Clinical Oncology, 2007, 25, 2480-2482
16.917Citations (PDF)
165The Close Relationship between South African and Latin American HTLV Type 1 Strains Corroborated in a Molecular Epidemiological Study of the HTLV Type 1 Isolates from a Blood Donor Cohort
AIDS Research and Human Retroviruses, 2007, 23, 503-507
1.416Citations (PDF)
166Estimating the Relative Contribution of dNTP Pool Imbalance and APOBEC3G/3F Editing to HIV Evolution In Vivo
Journal of Computational Biology, 2007, 14, 1105-1114
1.528Citations (PDF)
167Recombination Confounds the Early Evolutionary History of Human Immunodeficiency Virus Type 1: Subtype G Is a Circulating Recombinant Form
Journal of Virology, 2007, 81, 8543-8551
3.686Citations (PDF)
168Phylogenetic Surveillance of Viral Genetic Diversity and the Evolving Molecular Epidemiology of Human Immunodeficiency Virus Type 1
Journal of Virology, 2007, 81, 13050-13056
3.681Citations (PDF)
169Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation
Current Opinion in HIV and AIDS, 2007, 2, 123-129
3.323Citations (PDF)
170Impact of genetic variation of HIV-1 on drug resistance development
Future Virology, 2007, 2, 303-310
1.10Citations (PDF)
171No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs
Journal of Clinical Virology, 2007, 39, 43-47
3.039Citations (PDF)
172Human T-lymphotropic virus 1: recent knowledge about an ancient infection
Lancet Infectious Diseases, The, 2007, 7, 266-281
16.5654Citations (PDF)
173Limitations to Contact Tracing And Phylogenetic Analysis in Establishing HIV Type 1 Transmission Networks in Cuba
AIDS Research and Human Retroviruses, 2007, 23, 347-356
1.440Citations (PDF)
174Phylogeny of primate T lymphotropic virus type 1 (PTLV-1) including various new Asian and African non-human primate strains
Infection, Genetics and Evolution, 2007, 7, 374-381
2.334Citations (PDF)
175Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways
Infection, Genetics and Evolution, 2007, 7, 600-603
2.37Citations (PDF)
176Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors
Infection, Genetics and Evolution, 2007, 7, 382-390
2.330Citations (PDF)
177HIV forensics: pitfalls and acceptable standards in the use of phylogenetic analysis as evidence in criminal investigations of HIV transmission*
HIV Medicine, 2007, 8, 382-387
2.878Citations (PDF)
178Frequent HTLV-1 infection in the offspring of Peruvian women with HTLV-1-associated myelopathy/tropical spastic paraparesis or strongyloidiasis
Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2007, 22, 223-230
1.133Citations (PDF)
179Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000–2004
Virus Research, 2006, 118, 156-163
2.629Citations (PDF)
180Use of Electronic Monitoring Induces a 40-Day Intervention Effect in HIV Patients
Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 247-248
1.845Citations (PDF)
181Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity
Aids, 2006, 20, 1521-1529
2.533Citations (PDF)
182The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes
Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 352-360
1.892Citations (PDF)
183Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients
FEMS Immunology and Medical Microbiology, 2006, 46, 53-62
3.041Citations (PDF)
184Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART
Virology, 2006, 348, 35-46
2.327Citations (PDF)
185Algorithms for the interpretation of HIV-1 genotypic drug resistance information
Antiviral Research, 2006, 71, 335-342
3.856Citations (PDF)
186A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes
Journal of Virological Methods, 2006, 132, 181-186
1.616Citations (PDF)
187Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance
Bioinformatics, 2006, 22, 2975-2979
4.761Citations (PDF)
188Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent
Antimicrobial Agents and Chemotherapy, 2006, 50, 694-701
4.178Citations (PDF)
189Investigation of Baseline Susceptibility to Protease Inhibitors in HIV-1 Subtypes C, F, G and Crf02_Ag
Antiviral Therapy, 2006, 11, 581-589
1.960Citations (PDF)
190Molecular testing of multiple HIV-1 transmissions in a criminal case
Aids, 2005, 19, 1649-1658
2.544Citations (PDF)
191Mutations in Bothenvandgaggenes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology
Antiviral Chemistry and Chemotherapy, 2005, 16, 253-266
0.86Citations (PDF)
192Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G
Aids, 2005, 19, 1799-1806
2.578Citations (PDF)
193Re-analysis of 34 full-length HIV-1 intersubtype recombinant sequences
Infection, Genetics and Evolution, 2005, 5, 225-229
2.34Citations (PDF)
194HIV-1 genetic variants circulation in the North of Angola
Infection, Genetics and Evolution, 2005, 5, 231-237
2.321Citations (PDF)
195A Bayesian statistical analysis of human T-cell lymphotropic virus evolutionary rates
Infection, Genetics and Evolution, 2005, 5, 291-298
2.336Citations (PDF)
196Analysis of complex HIV-1 intersubtype recombinants using a Bayesian scanning method
Infection, Genetics and Evolution, 2005, 5, 219-224
2.33Citations (PDF)
197A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene
Journal of Virological Methods, 2005, 123, 25-34
1.639Citations (PDF)
198Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes
Journal of Virological Methods, 2005, 128, 47-53
1.634Citations (PDF)
199Circulation of genetically distinct contemporary human coronavirus OC43 strains
Virology, 2005, 337, 85-92
2.379Citations (PDF)
200Different Epidemic Potentials of the HIV-1B and C Subtypes
Journal of Molecular Evolution, 2005, 60, 598-605
1.747Citations (PDF)
201Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration
PLoS Medicine, 2005, 2, e112
8.0266Citations (PDF)
202SlidingBayes: exploring recombination using a sliding window approach based on Bayesian phylogenetic inference
Bioinformatics, 2005, 21, 1274-1275
4.721Citations (PDF)
203Genetic Variability and Molecular Evolution of the Human Respiratory Syncytial Virus Subgroup B Attachment G Protein
Journal of Virology, 2005, 79, 9157-9167
3.6139Citations (PDF)
204Evolutionary Dynamics of Human Retroviruses Investigated Through Full-Genome Scanning
Molecular Biology and Evolution, 2005, 22, 942-951
4.728Citations (PDF)
205Prevalence of Drug‐Resistant HIV‐1 Variants in Untreated Individuals in Europe: Implications for Clinical Management
Journal of Infectious Diseases, 2005, 192, 958-966
3.7388Citations (PDF)
206Molecular Footprint of Drug-Selective Pressure in a Human Immunodeficiency Virus Transmission Chain
Journal of Virology, 2005, 79, 11981-11989
3.672Citations (PDF)
207Complete Genomic Sequence of Human Coronavirus OC43: Molecular Clock Analysis Suggests a Relatively Recent Zoonotic Coronavirus Transmission Event
Journal of Virology, 2005, 79, 1595-1604
3.6558Citations (PDF)
208An automated genotyping system for analysis of HIV-1 and other microbial sequences
Bioinformatics, 2005, 21, 3797-3800
4.7483Citations (PDF)
209Fatal brain necrosis in primary HIV infection
Lancet, The, 2005, 366, 866
62.112Citations (PDF)
210Full-Length HIV Type 1 Genome Analysis Showing Evidence for HIV Type 1 Transmission from a Nonprogressor to Two Recipients Who Progressed to AIDS
AIDS Research and Human Retroviruses, 2005, 21, 575-579
1.417Citations (PDF)
211Title is missing!
Retrovirology, 2005, 2, 41
3.522Citations (PDF)
212Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant Lectins
Journal of Virology, 2004, 78, 10617-10627
3.695Citations (PDF)
213Clinical Characteristics of Patients in Peru with Human T Cell Lymphotropic Virus Type 1–Associated Tropical Spastic Paraparesis
Clinical Infectious Diseases, 2004, 39, 939-944
5.293Citations (PDF)
214HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy
Journal of Leukocyte Biology, 2004, 76, 562-570
2.934Citations (PDF)
215Mapping Sites of Positive Selection and Amino Acid Diversification in the HIV Genome
Genetics, 2004, 167, 1047-1058
4.249Citations (PDF)
216The Molecular Population Genetics of HIV-1 Group O
Genetics, 2004, 167, 1059-1068
4.2110Citations (PDF)
217Rising Prevalence of HIV-1 Non-B Subtypes in Belgium: 1983???2001
Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 279-285
1.849Citations (PDF)
218Molecular Evolution and Circulation Patterns of Human Respiratory Syncytial Virus Subgroup A: Positively Selected Sites in the Attachment G Glycoprotein
Journal of Virology, 2004, 78, 4675-4683
3.6115Citations (PDF)
219Simian T-Cell Leukemia Virus (STLV) Infection in Wild Primate Populations in Cameroon: Evidence for Dual STLV Type 1 and Type 3 Infection in Agile Mangabeys ( Cercocebus agilis )
Journal of Virology, 2004, 78, 4700-4709
3.662Citations (PDF)
220Prevalence and Correlates of Nonadherence to Antiretroviral Therapy in a Population of HIV Patients Using Medication Event Monitoring System®
AIDS Patient Care and STDs, 2004, 18, 644-657
2.676Citations (PDF)
221Analysis of the Serotype and Genotype Correlation of VP1 and the 5′ Noncoding Region in an Epidemiological Survey of the Human Enterovirus B Species
Journal of Clinical Microbiology, 2004, 42, 963-971
4.059Citations (PDF)
222Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory
Journal of Virological Methods, 2004, 119, 45-49
1.626Citations (PDF)
223Phylogenetic Reconstruction of a Known HIV-1 CRF04_cpx Transmission Network Using Maximum Likelihood and Bayesian Methods
Journal of Molecular Evolution, 2004, 59, 709-717
1.726Citations (PDF)
224Phylogenetic analysis of the full-length SARS-CoV sequences: Evidence for phylogenetic discordance in three genomic regions
Journal of Medical Virology, 2004, 74, 369-372
3.623Citations (PDF)
225Stabilisation of emulsions using hydrophobically modified inulin (polyfructose)
Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2004, 250, 133-140
5.237Citations (PDF)
226Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system
Journal of Clinical Virology, 2004, 31, 7-15
3.01Citations (PDF)
227Current Levels of Drug Resistance Among Therapy-Naive HIV-Infected Patients Have Significant Impact on Treatment Response
Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1664-1666
1.825Citations (PDF)
228A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses
Journal of Virological Methods, 2003, 108, 67-74
1.620Citations (PDF)
229Viral evolution and molecular epidemiology – evolving viruses and evolving analysis techniques
FEMS Immunology and Medical Microbiology, 2003, 39, 95-96
3.01Citations (PDF)
230Site stripping based on likelihood ratio reduction is a useful tool to evaluate the impact of non-clock-like behavior on viral phylogenetic reconstructions
FEMS Immunology and Medical Microbiology, 2003, 39, 125-132
3.010Citations (PDF)
231Performance of the VERSANT®HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
FEMS Immunology and Medical Microbiology, 2003, 39, 119-124
3.010Citations (PDF)
232Tracing the origin and history of the HIV-2 epidemic
Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6588-6592
7.5322Citations (PDF)
233Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV 1) infection among ethnically and geographically diverse Peruvian women
International Journal of Infectious Diseases, 2003, 7, 132-137
2.162Citations (PDF)
234Tenofovir Resistance and Resensitization
Antimicrobial Agents and Chemotherapy, 2003, 47, 3478-3484
4.186Citations (PDF)
235Mosaic Genomes of the Six Major Primate Lentivirus Lineages Revealed by Phylogenetic Analyses
Journal of Virology, 2003, 77, 7202-7213
3.637Citations (PDF)
236U.S. Human Immunodeficiency Virus Type 1 Epidemic: Date of Origin, Population History, and Characterization of Early Strains
Journal of Virology, 2003, 77, 6359-6366
3.6112Citations (PDF)
237The Low Evolutionary Rate of Human T-Cell Lymphotropic Virus Type-1 Confirmed by Analysis of Vertical Transmission Chains
Molecular Biology and Evolution, 2003, 21, 603-611
4.760Citations (PDF)
238Brazilian HTLV Type 2a Strains from Intravenous Drug Users (IDUs) Appear to Have Originated from Two Sources: Brazilian Amerindians and European/North American IDUs
AIDS Research and Human Retroviruses, 2003, 19, 519-523
1.430Citations (PDF)
239Globin Haplotypes of Human T-Cell Lymphotropic Virus Type I–Infected Individuals in Salvador, Bahia, Brazil, Suggest a Post-Columbian African Origin of This Virus
Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 536-542
1.828Citations (PDF)
240Analysis of the Evolutionary Relationships of HIV-1 and SIVcpz Sequences Using Bayesian Inference: Implications for the Origin of HIV-1
Molecular Biology and Evolution, 2003, 20, 1986-1996
4.730Citations (PDF)
241HIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible for Discordances Between Genotypic Drug Resistance Interpretation Algorithms
Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 8-14
1.886Citations (PDF)
242Western blot seroindeterminate individuals for Human T-lymphotropic Virus 1/2 (HTLV-1/2) in Fortaleza (Brazil): a serological and molecular diagnostic and epidemiological approach
Brazilian Journal of Infectious Diseases, 2003, 7, 202-209
0.216Citations (PDF)
243Short Communication: Lack of Evidence for Infection with Simian Immunodeficiency Virus in Bonobos
AIDS Research and Human Retroviruses, 2002, 18, 213-216
1.412Citations (PDF)
244A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export
Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 14440-14445
7.5130Citations (PDF)
245Initiation of HAART in Drug-Naive HIV Type 1 Patients Prevents Viral Breakthrough for a Median Period of 35.5 Months in 60% of the Patients
AIDS Research and Human Retroviruses, 2002, 18, 419-426
1.422Citations (PDF)
246Characterization of a Novel Simian Immunodeficiency Virus with a vpu Gene from Greater Spot-Nosed Monkeys (Cercopithecus nictitans) Provides New Insights into Simian/Human Immunodeficiency Virus Phylogeny
Journal of Virology, 2002, 76, 8298-8309
3.6125Citations (PDF)
247Nonadherence to Highly Active Antiretroviral Therapy: Clinically Relevant Patient Categorization Based on Electronic Event Monitoring
AIDS Research and Human Retroviruses, 2002, 18, 327-330
1.425Citations (PDF)
248env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors
Antimicrobial Agents and Chemotherapy, 2002, 46, 3954-3962
4.139Citations (PDF)
249A Combination of Poor Adherence and a Low Baseline Susceptibility Score is Highly Predictive for HAART Failure
Antiviral Chemistry and Chemotherapy, 2002, 13, 231-240
0.816Citations (PDF)
250Reanalysis of the HIV-1 Circulating Recombinant Form A/E (CRF01_AE): Evidence of A/E/G Recombination
Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 124-129
1.80Citations (PDF)
251Reanalysis of the HIV-1 Circulating Recombinant Form A/E (CRF01_AE): Evidence of A/E/G Recombination
Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 124-129
1.85Citations (PDF)
252Human Retroviruses (HIV and HTLV) in Brazilian Indians: Seroepidemiological Study and Molecular Epidemiology of HTLV Type 2 Isolates
AIDS Research and Human Retroviruses, 2002, 18, 71-77
1.456Citations (PDF)
253Phylogenetic classification of TT virus groups based on the N22 region is unreliable
Virus Research, 2002, 85, 47-59
2.615Citations (PDF)
254Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999
Virus Research, 2002, 85, 95-107
2.637Citations (PDF)
255Hepatitis C Virus Evolutionary Patterns Studied Through Analysis of Full-Genome Sequences
Journal of Molecular Evolution, 2002, 54, 62-70
1.775Citations (PDF)
256Complete Genome Sequence, Taxonomic Assignment, and Comparative Analysis of the Untranslated Regions of the Modoc Virus, a Flavivirus with No Known Vector
Virology, 2002, 293, 125-140
2.349Citations (PDF)
257Comparison of CREB- and NF-κB-Mediated Transactivation by Human T Lymphotropic Virus Type II (HTLV-II) and Type I (HTLV-I) Tax Proteins
Virology, 2002, 295, 182-189
2.325Citations (PDF)
258Comparative Rates of Nucleotide Sequence Variation in the Hypervariable Region of E1/E2 and the NS5b Region of Hepatitis C Virus in Patients with a Spectrum of Liver Disease Resulting from a Common Source of Infection
Virology, 2002, 301, 354-364
2.319Citations (PDF)
259A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients
Antiviral Therapy, 2002, 7, 123-129
1.9130Citations (PDF)
260A Rapid Phenotypic Assay for Detecting Multiple Nucleoside Analogue Reverse Transcriptase Inhibitor-Resistant HIV-1 in Plasma
Antiviral Therapy, 2002, 7, 131-139
1.93Citations (PDF)
261Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype
Aids, 2001, 15, 553-561
2.516Citations (PDF)
262Evaluation of Two Commercial Kits for the Detection of Genotypic Drug Resistance on a Panel of HIV Type 1 Subtypes A Through J
Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 254-258
1.841Citations (PDF)
263Increasing Prevalence of Non–Clade B HIV-1 Strains in Heterosexual Men and Women, as Monitored by Analysis of Reverse Transcriptase and Protease Sequences
Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 499-505
1.844Citations (PDF)
264Site-Directed Mutagenesis of Human Immunodeficiency Virus Type 1 Reverse Transcriptase at Amino Acid Position 138
Virology, 2001, 280, 97-106
2.322Citations (PDF)
265A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors
Journal of Virological Methods, 2001, 96, 183-188
1.626Citations (PDF)
266Increasing Prevalence of Non–Clade B HIV-1 Strains in Heterosexual Men and Women, as Monitored by Analysis of Reverse Transcriptase and Protease Sequences
Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 499-505
1.870Citations (PDF)
267Dating the Origin of the African Human T-Cell Lymphotropic Virus Type-I (HTLV-I) Subtypes
Molecular Biology and Evolution, 2001, 18, 661-671
4.7124Citations (PDF)
268Evidence for a Second Simian T-Cell Lymphotropic Virus Type 3 in Cercopithecus nictitans from Cameroon
Journal of Virology, 2001, 75, 11939-11941
3.628Citations (PDF)
269Therapiefalen bij HIV en AIDS: belang en aanpak van de onderliggende factoren
Tijdschrift Voor Geneeskunde, 2001, 57, 782-787
0.00Citations (PDF)
270Evaluation of Two Commercial Kits for the Detection of Genotypic Drug Resistance on a Panel of HIV Type 1 Subtypes A Through J
Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 254-258
1.81Citations (PDF)
271Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance
Aids, 2000, 14, 1731-1738
2.551Citations (PDF)
272Blinded, multicenter quality control study for the quantification of human immunodeficiency virus type 1 RNA in plasma by the Belgian AIDS reference laboratories
Clinical Microbiology and Infection, 2000, 6, 213-217
5.324Citations (PDF)
273Origins of HTLV-1 in South America (letter 2)
Nature Medicine, 2000, 6, 232-233
33.015Citations (PDF)
274Isolation, Cloning, and Complete Nucleotide Sequence of a Phenotypically Distinct Brazilian Isolate of Human T-Lymphotropic Virus Type II (HTLV-II)
Virology, 2000, 271, 142-154
2.338Citations (PDF)
275Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues
Antimicrobial Agents and Chemotherapy, 2000, 44, 2109-2117
4.1102Citations (PDF)
276Baseline HIV Type 1 Genotypic Resistance to a Newly Added Nucleoside Analog Is Predictive of Virologic Failure of the New Therapy
AIDS Research and Human Retroviruses, 2000, 16, 529-537
1.416Citations (PDF)
277Tempo and Mode of Human and Simian T-Lymphotropic Virus (HTLV/STLV) Evolution Revealed by Analyses of Full-Genome Sequences
Molecular Biology and Evolution, 2000, 17, 374-386
4.775Citations (PDF)
278Presence of 2' ,5'-Bis-O-(tert-butyldimethylsilyl)-3-spiro-5"(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO)-Resistant Virus Strains in TSAO-Inexperienced HIV Patients
AIDS Research and Human Retroviruses, 2000, 16, 825-833
1.49Citations (PDF)
279Evolutionary strategies of human T-cell lymphotropic virus type II
Gene, 2000, 261, 171-180
2.330Citations (PDF)
280A Second Target for the Peptoid Tat/Transactivation Response Element Inhibitor CGP64222: Inhibition of Human Immunodeficiency Virus Replication by Blocking CXC-Chemokine Receptor 4-Mediated Virus Entry
Molecular Pharmacology, 2000, 57, 116-124
2.639Citations (PDF)
281Human Immunodeficiency Virus Gene Regulation as a Target for Antiviral Chemotherapy
Antiviral Chemistry and Chemotherapy, 1999, 10, 1-14
0.834Citations (PDF)
282Full-Length Genomic Sequence of an HIV Type 1 Subtype G from Kinshasa
AIDS Research and Human Retroviruses, 1999, 15, 585-589
1.47Citations (PDF)
283Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood
European Journal of Clinical Investigation, 1999, 29, 445-452
3.021Citations (PDF)
284The discovery of two new divergent STLVs has implications for the evolution and epidemiology of HTLVs
1999, 9, 155-170
29Citations (PDF)
285Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors
Journal of Clinical Virology, 1999, 13, 71-80
3.093Citations (PDF)
286The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy
Gene, 1999, 234, 11-21
2.332Citations (PDF)
287Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV
Aids, 1999, 13, 1477-1483
2.582Citations (PDF)
288Different population dynamics of human T cell lymphotropic virus type II in intravenous drug users compared with endemically infected tribes
Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 13253-13258
7.584Citations (PDF)
289HTLV-I PREVALENCE AMONG SERONEGATIVE ETHNC JEWISH PEOPLE IN BUKHARA (UZBEKISTAN)
Journal of Acquired Immune Deficiency Syndromes, 1999, 20, A59
0.30Citations (PDF)
290THE EVOLUTIONARY RATE OF HTLV-II IN INJECTING DRUG USERS IS 50 TO 200 TIMES FASTER COMPARED TO IN ENDEMICALLY INFECTED AMERINDIAN AND PYGMY TRIBES
Journal of Acquired Immune Deficiency Syndromes, 1999, 20, A76
0.30Citations (PDF)
291HTLV-1 PREVALENCE AMONG SERONEGATIVE ETHNIC JEWISH PEOPLE IN BUKHARA (UZBEKISTAN)
Journal of Acquired Immune Deficiency Syndromes, 1999, 20, A51
0.30Citations (PDF)
292The Simian T-Lymphotropic Virus STLV-PP1664 fromPan paniscusIs Distinctly Related to HTLV-2 but Differs in Genomic Organization
Virology, 1998, 243, 366-379
2.336Citations (PDF)
293Two New Human T-Lymphotropic Virus Type I Phylogenetic Subtypes in Seroindeterminates, a Mbuti Pygmy and a Gabonese, Have Closest Relatives among African STLV-I Strains
Virology, 1998, 246, 277-287
2.383Citations (PDF)
294Diagnosis of human immunodeficiency virus infection by a polymerase chain reaction assay evaluated in patients harbouring strains of diverse geographical origin
Journal of Virological Methods, 1998, 70, 153-166
1.67Citations (PDF)
295Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations
Journal of Virological Methods, 1998, 73, 77-82
1.634Citations (PDF)
296Evolutionary Rate and Genetic Heterogeneity of Human T-Cell Lymphotropic Virus Type II (HTLV-II) Using Isolates from European Injecting Drug Users
Journal of Molecular Evolution, 1998, 46, 602-611
1.749Citations (PDF)
297Short Communication : Sequence Analysis of the First HTLV-I Infection in Germany without Relations to Endemic Areas
AIDS Research and Human Retroviruses, 1998, 14, 1199-1203
1.418Citations (PDF)
298Failure to Quantify Viral Load with Two of the Three Commercial Methods in a Pregnant Woman Harboring an HIV Type 1 Subtype G Strain
AIDS Research and Human Retroviruses, 1998, 14, 453-459
1.468Citations (PDF)
299Anti-Human Immunodeficiency Virus Drug Combination Strategies
Antiviral Chemistry and Chemotherapy, 1998, 9, 187-203
0.8111Citations (PDF)
300Stereospecificity of 6'-C-Neplanocin A Analogues as Inhibitors of S-Adenosylhomocysteine Hydrolase Activity and Human Immunodeficiency Virus Replication
Nucleosides, Nucleotides and Nucleic Acids, 1998, 17, 479-486
1.63Citations (PDF)
301Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
Aids, 1998, 12, 2007-2015
2.577Citations (PDF)
302A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152.
Journal of General Virology, 1998, 79, 1347-1352
3.313Citations (PDF)
303African Origin of Human T-Lymphotropic Virus Type 2 (HTLV-2) Supported by a Potential New HTLV-2d Subtype in Congolese Bambuti Efe Pygmies
Journal of Virology, 1998, 72, 4327-4340
3.680Citations (PDF)
304Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy
Antiviral Therapy, 1998, 3, 81-88
1.910Citations (PDF)
305Simian T Cell Leukemia Virus Type I from Naturally Infected Feral Monkeys from Central and West Africa Encodes a 91-Amino Acid p12 (ORF-I) Protein as Opposed to a 99-Amino Acid Protein Encoded by HTLV Type I from Humans
AIDS Research and Human Retroviruses, 1997, 13, 425-432
1.412Citations (PDF)
306Phylogenetic Analysis of a Simian T Lymphotropic Virus Type I from a Hamadryas Baboon
AIDS Research and Human Retroviruses, 1997, 13, 1545-1548
1.411Citations (PDF)
307Sequence Analysis of Two HTLV Type I Infections Imported to Germany
AIDS Research and Human Retroviruses, 1997, 13, 1255-1258
1.414Citations (PDF)
308Cell Type-Dependent Effect of Sodium Valproate on Human Immunodeficiency Virus Type 1 Replication in Vitro
AIDS Research and Human Retroviruses, 1997, 13, 187-192
1.447Citations (PDF)
309Development of Resistance of Human Immunodeficiency Virus Type 1 to Dextran Sulfate Associated with the Emergence of Specific Mutations in the Envelope gp120 Glycoprotein
Molecular Pharmacology, 1997, 52, 98-104
2.677Citations (PDF)
310S-Adenosylhomocysteine Hydrolase Inhibitors Interfere with the Replication of Human Immunodeficiency Virus Type 1 through Inhibition of the LTR Transactivation
Molecular Pharmacology, 1997, 52, 1157-1163
2.630Citations (PDF)
311Disulfide-containing macrolides that inhibit a late stage of the replicative cycle of human immunodeficiency virus
Antiviral Research, 1997, 34, A48
3.80Citations (PDF)
312New 1,1,3-trioxo-2H,4H-thieno[3,4-e]thiadiazine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase
Antiviral Research, 1997, 34, A56
3.80Citations (PDF)
313Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology
Journal of Medical Virology, 1997, 52, 1-7
3.679Citations (PDF)
314BaEV is a relic from an ancient retrovirus that crossed species barriers
Trends in Microbiology, 1996, 4, 478
8.11Citations (PDF)
315Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
Aids, 1996, 10, 995-999
2.5112Citations (PDF)
316Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC
Aids, 1996, 10, F61-F66
2.518Citations (PDF)
317Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1
Antiviral Research, 1996, 29, 297-307
3.840Citations (PDF)
318The three human T-lymphotropic virus type I subtypes arose from three geographically distinct simian reservoirs
Journal of General Virology, 1996, 77, 359-368
3.381Citations (PDF)
319The genomic structure of a new simian T-lymphotropic virus, STLV-PH969, differs from that of human T-lymphotropic virus types I and II
Journal of General Virology, 1996, 77, 347-358
3.342Citations (PDF)
320The presence of a divergent T-lymphotropic virus in a wild-caught pygmy chimpanzee (Pan paniscus) supports an African origin for the human T-lymphotropic/simian T-lymphotropic group of viruses
Journal of General Virology, 1996, 77, 1089-1099
3.370Citations (PDF)
321Complete nucleotide sequence of the Italian human T-cell lymphotropic virus type II isolate Gu and phylogenetic identification of a possible origin of South European epidemics
Journal of General Virology, 1996, 77, 1193-1201
3.337Citations (PDF)
322Questions on the Evolution of Primate T-Lymphotropic Viruses Raised by Molecular and Epidemiological Studies of Divergent Strains
Journal of Acquired Immune Deficiency Syndromes, 1996, 13, S242-S247
0.315Citations (PDF)
323Proviral HTLV-I and HTLV-II in the Efe Pygmies of Northeastern Zaire
Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 208
0.315Citations (PDF)
324Quantification of HIV-1 RNA in Plasma: Comparable Results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV Monitor Test
Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 127-139
0.395Citations (PDF)
325Standardisation of primers and an algorithm for HIV-1 diagnostic PCR evaluated in patients harbouring strains of diverse geographical origin
Journal of Virological Methods, 1995, 51, 305-316
1.682Citations (PDF)
326Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR
Journal of Virological Methods, 1995, 52, 121-132
1.663Citations (PDF)
327HTLV-Negative and HTLV Type I-Positive Tropical Spastic Paraparesis in Northeastern Brazil
AIDS Research and Human Retroviruses, 1995, 11, 315-318
1.418Citations (PDF)
328Inhibition of HIV Type 1 Tat-Mediated trans -Activation by Oncostatin M in HLtat Cells
AIDS Research and Human Retroviruses, 1995, 11, 1355-1358
1.410Citations (PDF)
329Characterization of HIV-1 Strains Isolated from Patients Treated with TIBO R82913
AIDS Research and Human Retroviruses, 1994, 10, 39-46
1.450Citations (PDF)
330Familial Transmission and Minimal Sequence Variability of Human T-Lymphotropic Virus Type I (HTLV-I) in Zaire
AIDS Research and Human Retroviruses, 1994, 10, 1135-1142
1.450Citations (PDF)
331Primate T-Lymphotropic Virus Type I LTR Sequence Variation and Its Phylogenetic Analysis: Compatibility with an African Origin of PTLV-I
Virology, 1994, 202, 212-223
2.3103Citations (PDF)
332A primate T-lymphotropic virus, PTLV-L, different from human T-lymphotropic viruses types I and II, in a wild-caught baboon (Papio hamadryas).
Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2848-2852
7.5113Citations (PDF)
333HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity against HIV-1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase
Virology, 1993, 192, 246-253
2.3171Citations (PDF)
334HTLV-II Seroprevalence in Pygmies Across Africa Since 1970
AIDS Research and Human Retroviruses, 1993, 9, 709-713
1.495Citations (PDF)
335Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.
Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 1711-1715
7.5206Citations (PDF)
336Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 6952-6956
7.591Citations (PDF)
337Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335
Antimicrobial Agents and Chemotherapy, 1992, 36, 2628-2633
4.149Citations (PDF)
3382',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.
Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4392-4396
7.5166Citations (PDF)
339Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis
Virology, 1992, 188, 900-904
2.355Citations (PDF)
340Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-d-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase
FEBS Journal, 1992, 205, 139-146
0.29Citations (PDF)
341Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase
Thrombosis and Haemostasis, 1992, 68, 170-179
4.123Citations (PDF)
342Construction and characterization of a functional chimeric murine - human antibody directed against human fibrin fragment-D dimer
FEBS Journal, 1991, 195, 235-242
0.216Citations (PDF)
343Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment-D dimer
FEBS Journal, 1990, 192, 767-775
0.211Citations (PDF)
344Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
Journal of Biological Chemistry, 1990, 265, 12184-12191
2.214Citations (PDF)
345Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium
Frontiers in Microbiology, 0, 10,
3.923Citations (PDF)
346More than one crisis: COVID-19 response actors navigating multi-dimensional crises in Flanders, Belgium
Critical Public Health, 0, 33, 566-578
2.13Citations (PDF)